Quick Summary:
In the rapidly evolving and highly lucrative landscape of the global CAR T-cell Therapy market, staying abreast of the latest trends and industry developments is crucial for sustained growth. Our comprehensive Market Research Report, meticulously prepared by industry experts, offers deep insights into this burgeoning $9.6 billion field, providing you with competitive knowledge to optimize your strategic planning and decision-making.
This report conducts an in-depth analysis on a range of key metrics, including anticipated growth rates, key geographical markets, and a snapshot of significant competitors. Inclusive of unique market presence data across multiple geographies, it affords a detailed view into the industry's terrain. Moreover, subscribers will benefit from online interactive peer-to-peer collaborative bespoke updates, access to a robust digital research platform, and complimentary updates for one year, securing a real-time tactical advantage in this dynamic field.
Global CAR T-cell Therapy Market to Reach $9.6 Billion by 2030
The global market for CAR T-cell Therapy estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$9.6 Billion by 2030, growing at a CAGR of 21.9% over the analysis period 2022-2030. DLBCL, one of the segments analyzed in the report, is projected to record 18.7% CAGR and reach US$4.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the ALL segment is readjusted to a revised 25.6% CAGR for the next 8-year period.The U.S. Market is Estimated at $610.5 Million, While China is Forecast to Grow at 21.4% CAGR
The CAR T-cell Therapy market in the U.S. is estimated at US$610.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 21.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.9% and 18.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 15.3% CAGR.Select Competitors (Total 12 Featured) -
- bluebird bio, Inc.
- CARsgen Therapeutics
- Celgene Corporation
- Gilead Sciences, Inc.
- Novartis AG
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for CAR T-cell Therapy?
What is the growth rate of the Global Market for CAR T-cell Therapy?
What is the forecasted size of the Global Market for CAR T-cell Therapy?
Who are the key companies in the Global Market for CAR T-cell Therapy?
Report Attribute | Details |
---|---|
No. of Pages | 179 |
Published | December 2023 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 2 Billion |
Forecasted Market Value ( USD | $ 9.6 Billion |
Compound Annual Growth Rate | 21.7% |
Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- bluebird bio, Inc.
- CARsgen Therapeutics
- Celgene Corporation
- Gilead Sciences, Inc.
- Novartis AG